Drug Trial Radar · NCT06797973
Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean Section
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,312
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
May 31, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Anne Juul WikkelsøAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if morphine added to the spinal anaesthesia can improve postoperative pain treatment for patients undergoing caesarean section, without increasing the risk of serious adverse events in mother and baby. The main questions it aims to answer are: * Is the treatment effective in preventing postoperative pain? * Is the treatment safe for both mother and baby? Participants will be given a normal spinal anaesthesia with addition of either morphine or sodium chloride (inactive substance). All participants will receive standard postoperative pain treatment, including morphine tablets as needed. Researchers will collect data from the electronic medical record and ask the participants to fill out questionnaires about pain levels and possible side effects.
Conditions
- Caesarean Section
- Postoperative Pain
Interventions
Intrathecal MorphineDrug
80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl
Placebo (Sodium Chloride Injection, 0.9%)Drug
0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Level of pain when mobilising from supine to sitting position within 24 hoursTime frame: 6, 12, 18 and 24 hours following spinal anaesthesia
- Maternal and neonatal serious adverse eventsTime frame: Within 7 days from discharge
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Aarhus University Hospital
Aarhus, Denmark · Recruiting
Copenhagen University Hospital - Rigshospitalet
Copenhagen, Denmark · Recruiting
Copenhagen University Hospital - Herlev and Gentofte, Herlev
Herlev, Denmark · Recruiting
Copenhagen University Hospital - North Zealand, Hillerød
Hillerød, Denmark · Recruiting
Regional Hospital Horsens
Horsens, Denmark · Recruiting
Copenhagen University Hospital - Amager and Hvidovre, Hvidovre
Hvidovre, Denmark · Recruiting
University Hospital of Southern Denmark - Lillebælt Hospital, Kolding
Kolding, Denmark · Recruiting
University Hospital of Southern Denmark - Odense University Hospital
Odense C, Denmark · Recruiting
Zealand University Hospital
Roskilde, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.